The SEQUENCE trial, which demonstrated Skyrizi’s superiority over Stelara, has further bolstered its standing in IBD treatment algorithms. While J&J’s Tremfya awaits regulatory approval in CD ...

J&J has said it will now need upfront payment in full for its anticoagulant Xarelto (rivaroxaban) and immunology therapy Stelara (ustekinumab), with a rebate paid later, rather than the previous ...